Laura K.  Campbell net worth and biography

Laura Campbell Biography and Net Worth

Insider of Athersys
Laura K. Campbell CPA serves as Senior Vice President - Finance of the Company. Ms. Campbell joined Athersys in January 1998 and has served as our Senior Vice President of Finance since March 2016. Ms. Campbell joined us as Controller from January 1998, followed by Director of Finance and Senior Director of Finance, and then served as our Vice President of Finance from June 2006 until March 2016. Prior to Athersys, she was at Ernst & Young LLP, a public accounting firm, for eleven years in the firm’s audit practice. During her tenure with Ernst & Young LLP, Ms. Campbell specialized in entrepreneurial services and the biotechnology industry sector and assisted in several initial public offerings. Ms. Campbell received her B.S., with distinction, in Business Administration from The Ohio State University and is a Certified Public Accountant.

What is Laura K. Campbell's net worth?

The estimated net worth of Laura K. Campbell is at least $2,316.68 as of March 16th, 2021. Ms. Campbell owns 413,692 shares of Athersys stock worth more than $2,317 as of March 28th. This net worth approximation does not reflect any other assets that Ms. Campbell may own. Learn More about Laura K. Campbell's net worth.

How do I contact Laura K. Campbell?

The corporate mailing address for Ms. Campbell and other Athersys executives is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. Athersys can also be reached via phone at (216) 431-9900 and via email at [email protected]. Learn More on Laura K. Campbell's contact information.

Has Laura K. Campbell been buying or selling shares of Athersys?

Laura K. Campbell has not been actively trading shares of Athersys during the last ninety days. Most recently, Laura K. Campbell sold 10,000 shares of the business's stock in a transaction on Tuesday, March 16th. The shares were sold at an average price of $1.97, for a transaction totalling $19,700.00. Following the completion of the sale, the insider now directly owns 413,692 shares of the company's stock, valued at $814,973.24. Learn More on Laura K. Campbell's trading history.

Who are Athersys' active insiders?

Athersys' insider roster includes Laura Campbell (Insider), John Harrington (EVP), Ismail Kola (Director), William Lehmann, Jr. (CEO), and Ivor Macleod (CFO). Learn More on Athersys' active insiders.

Laura K. Campbell Insider Trading History at Athersys

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/16/2021Sell10,000$1.97$19,700.00413,692View SEC Filing Icon  
12/15/2020Sell10,000$1.92$19,200.00432,175View SEC Filing Icon  
4/1/2020Sell137,894$3.81$525,376.14561,005View SEC Filing Icon  
3/30/2020Sell44,929$2.40$107,829.60561,005View SEC Filing Icon  
8/10/2018Sell28,868$2.01$58,024.68590,424View SEC Filing Icon  
8/8/2018Sell2,800$2.01$5,628.00590,424View SEC Filing Icon  
8/2/2018Sell14,420$2.01$28,984.20602,944View SEC Filing Icon  
2/1/2017Buy20,000$1.01$20,200.00501,815View SEC Filing Icon  
11/28/2012Buy10,000$1.01$10,100.00View SEC Filing Icon  
See Full Table

Laura K. Campbell Buying and Selling Activity at Athersys

This chart shows Laura K Campbell's buying and selling at Athersys by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Athersys Company Overview

Athersys logo
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.
Read More

Today's Range

Now: $0.01
Low: $0.01
High: $0.01

50 Day Range

MA: $0.01
Low: $0.01
High: $0.03

2 Week Range

Now: $0.01
Low: $0.01
High: $1.99

Volume

18,706 shs

Average Volume

1,765,480 shs

Market Capitalization

$345,626.40

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A